|
|
 |
|
Viewing report
|
|
|
|
Strategic Assessment of HTS in the Asia Pacific Life Sciences Market
Frost & Sullivan, Sep 2003
Genomics and Proteomics-led Drug Discovery Spurs Demand
The high throughput screening (HTS) market is set for greater growth owing to the recent advances in genomic and proteomic research that have increased the number of potential drug targets requiring HTS. Effective tools such as DNA microarrays and protein arrays are being increasingly employed in research, leading to the identification of more drug candidates for evaluation and a greater number of targets to be screened. Since only one in 1,000 compounds that enter pre-clinical testing will reach the human testing phase and only one out of five drugs tested on humans will be finally approved for sale, it is imperative for drug discovery majors to utilize a highly effective screening process. Pharmaceutical companies pressured by investors to bring more drugs to market increasingly prefer to use HTS to rapidly screen available compounds against the latest targets.
This new research service from Frost & Sullivan provides a strategic assessment of HTS with specific focus on the Asia Pacific life sciences market. It gives the reader a clear idea of the high throughput screening process and delineates its role in the modern drug discovery value chain. It discusses in detail the major technological trends in HTS, and the market factors driving these trends. It also provides growth strategies for established industry participants and new entrants.
Patent Protection and Increased Research Activity Aids Growth of the Market
Increased patent protection by the countries in the Asia Pacific region has lead to pharmaceutical and biotech companies in the area focusing more on drug discovery, thus paving the way for growth of the HTS market. The ensuing rise in screening activity promises healthy demand for HTS over the forecast period. With improved patent protection, there is also expected to be an increase in contract research in the region, which would augur well for HTS industry participants, says the analyst of this research service.
With most Asian countries becoming WTO signatories, lack of patent protection has ceased to be a deterrent, and this factor, along with the mushrooming of biotech companies in the region is expected to improve the market. HTS providers planning to enter the Asia Pacific market or expand operations in the region should focus on the research institutes and government labs of the region, since this increases the probability of sales, notes the analyst.
Natural Product-based Drug Discovery Prevalent in the Region Encourages Usage of HTS
The abundant biodiversity found in the Asia-Pacific region has resulted in unique alternative systems of medicine based on natural products. Currently, efforts are underway to discover novel drug candidates from these natural substances using modern biotechnology such as HTS. For example, in China and Taiwan, the Government as well as private companies are focusing on the screening of Traditional Chinese Medicine (TCM) for drug molecules.
Drug discovery companies in the Asia Pacific region need to capitalize on this strategic advantage and utilize the indigenous medicine practices of their countries to build libraries of natural compounds, which can be screened for activity, adds the analyst.
Customers who bought this item also bought
A Guide to HTS Assay Development
Strategic Analysis of the European High Throughput Screening (HTS) Market
High Throughput Screening
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Overview of the European Drug Discovery Market
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
GPCR - Drug Targets
Drug Discovery Technologies - A Global Update of Market Trends & Opportunities
U.S. High Throughput Screening Markets
Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates
High-Throughput Screening in Drug Discovery
Drug Discovery Markets in Asia Pacific
|
|
|
|
